Objective To determine the effect of pioglitazone plus metformin or a sulphonylurea on lipoprotein particle size and subclass distribution in patients with type 2 diabetes.
Methods Lipid profiles were determined for blood samples from patients participating in two randomised, double-blind, 24-week studies of pioglitazone 30 mg or 45 mg daily plus either metformin or a sulphonylurea.
Results Samples from 177 patients were evaluated; 96 of these patients received a sulphonylurea, and 81 received metformin. Pioglitazone combination treatment produced significant increases from baseline for average and peak low-density lipoprotein (LDL) particle size at weeks 12 and 24 (p<0.0001 for each; range 0.29–0.39 nm for average and 0.36–0.55 nm for peak particle size, respectively). Significant shifts in high-density lipoprotein (HDL) and LDL distribution showed an increase in large particles and a decrease in small particles. For pioglitazone plus metformin, significant increases in levels of apolipoprotein (Apo) AI, Apo AI/AII-containing HDL, and lipoprotein(a) also were noted, whereas Apo B levels decreased.
Conclusions These observed changes are thought to affect the atherogenic profile positively. Therefore, pioglitazone combination treatment may lead to decreased cardiovascular risk in patients with type 2 diabetes.
1. Kliewer SA, Xu HE, Lambert MH, Willson TM.Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res2001;56:239–63.
2.
2. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL.Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care2000;23:1605–11.
4. Franceschini G.Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease. Am J Cardiol2001;88:9N–13N.
5.
5. Gotto AM Jr.Triglyceride as a risk factor for coronary artery disease. Am J Cardiol1998;82:22Q–25Q.
6.
6. Turner RC, Millns H, Neil HA et al.Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ1998;316:823–8.
7.
7. Franz MJ, Bantle JP, Beebe CA et al.Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care2002;25:148–98.
8.
8. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation2002;106:3143–421.
9.
9. Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S.Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. The Pioglitazone 014 Study Group. Int J Clin Pract2002;56:251–7.
10.
10. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL.Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther2000;22:1395–409.
11.
11. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL.Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med2001;111:10–17.
12.
12. Fonseca V, Rosenstock J, Patwardhan R, Salzman A.Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA2000;283:1695–702.
13.
13. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J.A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. The Rosiglitazone Clinical Trials Study Group. Diabetes Care2001;24:1226–32.
14.
14. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A.Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. The Rosiglitazone Clinical Trials Study Group. Diabetes Care2001;24:308–15.
15.
15. Packard C, Caslake M, Shepherd J.The role of small, dense low density lipoprotein (LDL): a new look. Int J Cardiol2000;74(suppl 1):S17–S22.
16.
16. Winkler K, Konrad T, Fullert S et al.Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care2003;26:2588–94.
17.
17. Winkler K, Friedrich I, Baumstark MW, Wieland H, März W.Pioglitazone reduces atherogenic dense low density lipoprotein (LDL) particles in patients with type 2 diabetes mellitus. Br J Diabetes Vasc Dis2002;2:143–8.
18.
18. Tiffany TO.Fluorometry nephelometry and turbidimetry in: Burtis CA, Ashwood ER, eds. Tietz Textbook of Clinical Chemistry3rd edition. Philadelphia, PA. W B Saunders, 1999:94–112.
19.
19. Rainwater DL.Electrophoretic separation of LDL and HDL subclasses. Methods Mol Biol1998;110:137–51.
20.
20. Nguyen C, Charles MA.Atherogenic lipid phenotype and lipoprotein(a) in diabetes. Endocrinologist2002;12:243–59.
21.
21. van Wijk JP, de Koning EJ, Martens EP, Rabelink TJ.Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol2003;23:1744–9.
22.
22. Freed MI, Ratner R, Marcovina SM et al.Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. The Rosiglitazone Study 108 Investigators. Am J Cardiol2002;90:947–52.
23.
23. Garvey WT, Kwon S, Zheng D et al.Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes2003;52:453–62.
24.
24. Singh AT, Rainwater DL, Haffner SM et al.Effect of diabetes on lipoprotein size. Arterioscler Thromb Vasc Biol1995;15:1805–11.
25.
25. Austin MA.Plasma triglyceride and coronary heart disease. Arterioscler Thromb1991;11:2–14.
26.
26. Gardner CD, Fortmann SP, Krauss RM.Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA1996;276:875–81.
27.
27. Koba S, Hirano T, Kondo T et al.Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart disease. Am Heart J2002;144:1026–35.
28.
28. Laakso M, Lehto S, Penttila I, Pyorala K.Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation1993;88(4 pt 1):1421–30.
29.
29. Vakkilainen J, Steiner G, Ansquer JC et al.Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). The DAIS Group. Circulation2003;107:1733–7.
30.
30. Austin MA, Kamigaki A, Hokanson JE.Low-density lipoprotein particle size is a risk factor for coronary heart disease independent of triglyceride and HDL cholesterol: a meta-analysis of three prospective studies in men. Circulation1999;99:1124 (Abstract P93).
31.
31. Barzilai N, Atzmon G, Schechter C et al.Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA2003;290:2030–40.
32.
32. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E.High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet2001;358:2026–33.
33.
33. Lamarche B, Moorjani S, Lupien PJ et al.Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation1996;94:273–8.
34.
34. Hiraga T, Kobayashi T, Okubo M et al.Prospective study of lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients with diabetes. Diabetes Care1995;18:241–4.
35.
35. Ovalle F, Bell DS.Troglitazone's effect on lipoprotein(a) levels. Diabetes Care1999;22:859–60.
36.
36. Ko SH, Song KH, Ahn YB et al.The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus. Metabolism2003;52:731–4.
37.
37. Herz M, Johns D, Reviriego J et al.A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther2003;25:1074–95.
38.
38. King AB, Armstrong DU.Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review. Diabetes Technol Ther2002;4:145–51.
